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Background: Aortic occlusion is accompanied by a hyperdynamic cardiovascular response secondary to increased systemic
vascular resistance and increased cardiac output. This study was designed primarily to determine the safety and cardio-
vascular response to hydrogen sulﬁde (H2S; HS) administration with supraceliac aortic cross-clamp and, secondarily, on
short-duration resuscitation.
Methods: A validated porcine model (ﬁve sham swine compared with ﬁve controls) demonstrated a signiﬁcant hyper-
dynamic cardiovascular response to 35% blood volume hemorrhage, 50-minute suprarenal aortic cross-clamping, and 6-
hour resuscitation. Eight additional experimental swine were administered HS at 4 mg/min during aortic cross-clamping.
Results: During the cross-clamp period, hemodynamic curves of mean arterial pressure and heart rate demonstrated
a blunting effect with HS administration, with a signiﬁcant decrease being seen with mean arterial pressure at the end of the
cross-clamp period (120 vs 149 mmHg; P[ .04). Resuscitation requirements were signiﬁcantly reduced at 6 hours because
the HS cohort received 8 L less crystalloid (P[ .001) and 10.4 mg less epinephrine (P < .001). There was not a signiﬁcant
change in cardiac output, systemic vascular resistance, pulmonary vascular resistance, or pathologic liver analysis.
Conclusions: The administration of HS during the 50 minutes of supraceliac aortic cross-clamp signiﬁcantly reduced stress
of the left heart. On clamp release, HS signiﬁcantly reduced the need for volume and pressors. HS has positive beneﬁts
during cross-clamp and subsequent resuscitation, demonstrating that targeted pharmacologic therapy is possible to
minimize adverse physiologic changes with aortic occlusion. (J Vasc Surg 2015;61:224-30.)
Clinical Relevance: Hydrogen sulﬁde (H2S; HS) is a promising new drug that has previously demonstrated beneﬁt in
minimizing injury from ischemia-reperfusion insults. For the ﬁrst time in a large animal model, HS attenuated the adverse
hyperdynamic cardiovascular response by minimizing left heart stress after hemorrhage and a 50-minute supraceliac aortic
cross-clamp. HS also decreased postclamp resuscitative requirements and demonstrated that targeted pharmacologic
therapy is possible to minimize adverse physiologic changes with aortic occlusion.Aortic occlusion is a critical part of many vascular
surgical procedures, as are ischemia-reperfusion insults in
elective and emergent vascular scenarios.1,2 Pharmacologic
abatement of the ischemic injury during aortic clamping,
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supplemented with free radical scavenging and, more
recently, with “cellular priming” with agents that minimize
stress at the cellular level.3,4 These agents potentially
pretreat cells to confer subsequent injury tolerance.
Hydrogen sulﬁde (H2S; HS) is such an agent and is
thought to work by minimizing the activation of the
systemic inﬂammatory cascade that occurs after ischemia-
reperfusion injuries. Although HS has demonstrated great
promise through protective histologic and cellular mecha-
nisms by attenuating oxidative stress and decreasing cellular
injury, clinical ﬁndings are needed to make it useful in
human clinical practice.5,6 Of particular interest, a murine
model demonstrated HS produced a state of “suspended
animation,” decreased inﬂammation after traumatic injury,
and improved survival from hemorrhage.5,7-9
Despite the promising results in the murine model,
porcine models have not demonstrated the same efﬁcacy
in cardiac arrest or after a hemorrhagic event.10,11
However, HS may have more promising beneﬁt after an
ischemia-reperfusion injury because it has been reported
to dampen the inﬂammatory cascade.12 By dampening
the inﬂammatory response, HS may allow ischemic toler-
ance and minimization of reperfusion injury. To be
Table I. Breakdown of the length and weights of the
study animals (no statistically signiﬁcant difference)
Group Length, cm Weight, kg
Sham 116.0 6 4.9 47.83 6 1.8
Control 115.5 6 2.9 44.52 6 3.5
HS 110.5 6 3.0 42.31 6 2.2
HS, Hydrogen sulﬁde.
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strate pharmacologic safety, without any adverse or lethal
events. Second, the drug must demonstrate the ability to
be administered and have a predictable clinical response.
Third, the clinical response must be understood in relation-
ship to the normal physiologic response. Therefore, the
primary purpose of this study was to determine the safety
and cardiovascular response to HS administration with
supraceliac aortic cross-clamp. In addition, this study was
designed secondarily to determine if HS provides a resusci-
tative beneﬁt after short-duration (6-hour) resuscitation.
METHODS
The animals used in this study were maintained and
housed in accordance with the “Guide for the Care and
Use of Laboratory Animals,” published by the National
Research Council/Institute of Laboratory Animal
Research.13 This study was approved by the Institutional
Animal Care and Use Committee.
Hemorrhagic shock and ischemia-reperfusion
injury model. Eighteen adult Yorkshire swine were
purchased from a U.S. Department of Agriculture-
approved Swine Research Facility. Animals were anes-
thetized, intubated, and vascular access was obtained to
continuously monitor central and peripheral cardiovascular
hemodynamics, as described previously.4 Hemorrhage
(35% of total circulating blood volume) was induced by
withdrawal through an inferior vena cava catheter over
30 minutes, followed by 50 minutes of ischemia from
a supraceliac aortic cross-clamp, followed by reperfusion
and a 6-hour resuscitative phase.14
Statistical analysis. Our power analysis determined
that 18 swine were necessary to determine differences in
coagulopathy, acidosis, and resuscitative requirements
with 90% conﬁdence using an a level of .05 after the
short-duration resuscitation.
Treatment groups. The 18 swine were divided into
three groups: ﬁve sham, ﬁve control, and eight experi-
mental swine that were administered HS at the time of
the supraceliac aortic cross-clamp.15 The sham group
underwent all procedures, with the exception of hemor-
rhage and cross-clamp, to keep times equal. HS was
prepared in 1 L of normal saline and administered at 4 mg/
kg continuously during the 50-minute cross clamp in
a total volume solution of 1 L. The sham and control
groups received 1 L of 0.9% normal saline at the same rate
to keep resuscitation volume equivalent during the cross-
clamp. In all groups, 1 L of normal saline or the experi-
mental HS solution infusion was started with cross-clamp
application.
Cross-clamp and resuscitation. During the 50-
minute supraceliac aortic cross-clamp period, invasive
hemodynamic parameters (via a pulmonary artery ther-
modilution catheter) were measured in all swine at the time
of cross-clamp application, every 15 minutes, and at cross-
clamp release. During this interval, mean arterial pressure
(MAP), heart rate (HR), and central venous and pulmo-
nary artery pressures were measured continuously.After the cross-clamp was released, all swine were
resuscitated by a standardized protocol, with goals being
to maintain MAP >40 mm Hg and central venous pressure
>4 mm Hg, while maintaining partial pressure of carbon
dioxide of 40 mmHg and oxygen saturations >92%. Labo-
ratory monitoring (arterial blood gas, complete blood
count, coagulation proﬁle) and invasive hemodynamic
monitoring was also done every 30 minutes.
The sham and control groups had a predictable hyper-
dynamic cardiovascular response to hemorrhage and the
subsequent supraceliac aortic cross-clamping. In addition,
when the swine were resuscitated for 6 hours, the amount
of ﬂuid required for resuscitation and the need for vaso-
pressors signiﬁcantly increased. This was therefore an
appropriate platform in which to test the HS administration
and speciﬁcally analyze the cardiovascular response during
medication administration and aortic cross-clamping.
Immediately after euthanasia, sections of liver were har-
vested and processed appropriately into 4-mm sections for
hematoxylin and eosin staining and coverslipping. Two
pathologists independently evaluated each tissue section
for microscopic evidence of hypoxia/ischemia-reperfusion
injury and then reviewed the histology together for
a consensus score. Tissue damage scores were integer
values from 1 to 5, with 1 being no tissue damage, and 5
being extensive necrosis, inﬂammation, and intracellular
microvesicular change, as previously reported.4
RESULTS
The 18 Yorkshire swine were matched by weight and
length between groups (Table I). Overall, HS decreased
the mean HR by 22 beats/min (P ¼ .03) and the average
MAP by 18 mm Hg (P ¼ .05). Temporal changes (Fig 1)
were also analyzed during the cross-clamp phase to deter-
mine differences that occurred between the left and right
heart pressures. Analysis of the temporal cross-clamp
showed left heart pressures were changed, in that the
hyperdynamic response was attenuated at 15, 30, and
45 minutes in the HS group (Fig 1). However, no signiﬁ-
cant change was noted in the systemic vascular resistance
(P ¼ .09) or cardiac output (P ¼ .25) among the groups.
At cross-clamp, MAP was 60 mm Hg in the control group
compared with 65 mm Hg with HS administration (P ¼
.34), but HS administration attenuated this response at
15 minutes (103 vs 141 mm Hg; P ¼ .21), 30 minutes
(125 vs 150 mm Hg; P ¼ .15), and 45 minutes (120 vs
149 mm Hg; P ¼ .04), with equal pressure 10 minutes
Fig 1. Temporal relationships of hemodynamic measurements are shown during the 50-minute supraceliac aortic
cross-clamp. Demonstrated in the (A) heart rate (HR) and (B) mean arterial blood pressure hemodynamic curves is the
attenuation of the normal physiologic response with 4 mg/kg hydrogen sulﬁde (H2S; HS) administration. C, Cardiac
output followed the normal physiologic curve and demonstrated greatest attenuation beyond 30 minutes. D, Right
heart and (E) pulmonary artery (PA) systolic (top) and diastolic (bottom) pressures were unchanged.
Fig 2. Resuscitation requirements are shown after 35% blood volume hemorrhage, 50-minute supraceliac aortic cross-
clamp, and 6-hour resuscitation. Volumes of intravenous ﬂuids and vasopressors are aggregate totals that were
administered as continuous infusions. The error bars indicate the standard deviation.
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(40.8 vs 40.6 mm Hg). The HR was not signiﬁcantly
decreased at cross-clamp application (P ¼ .53), 15 minutes
(P ¼ .09), 30 minutes (P ¼ .8), or 45 minutes (P ¼ .51)
but was decreased upon cross-clamp release (144 vs 183beats/min; P ¼ .011). Cardiac output was also attenuated,
but this did not begin until 30 minutes into the cross-
clamp and did not reach statistical signiﬁcance. An analysis
of the indirect work of the right heart showed there was no
signiﬁcant difference in the pulmonary artery systolic or
Fig 3. Histopathology of ischemia-reperfusion injury in swine
liver. A, In normal control liver (sham animal), scattered sinusoidal
lymphocytes (arrowheads) are seen, but otherwise the liver is
unremarkable. B, Liver from a pig that underwent cross-clamp and
hemorrhage, but received no pharmacotherapy (hemorrhagic
shock animal), shows extensive centrilobular zone 3 necrosis (area
within dotted line) and only a thin rim of normal zone 1 hepato-
cytes remain (area between solid arrowheads). C, Liver from a pig
that was administered hydrogen sulﬁde (H2S; HS) at cross-clamp
shows focal necrosis (black arrowheads), inﬂammation, and
diffuse hepatic sinusoidal dilatation (white arrowheads). Scale bar ¼
100 microns.
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in systemic vascular resistance, pulmonary vascular resis-
tance, and stroke volume.
During the entire 6-hour resuscitation period, ﬂuid and
pressor requirements were signiﬁcantly decreased in the HS
cohort compared with the control group (Fig 2). The HScohort received 8 L less crystalloid (11.1 6 2.1 vs 19.1 6
2.4 L; P ¼ .001) and 10.4 mg less epinephrine (2.6 6 0.5
vs 13.0 6 1.9 mg; P < .001). Laboratory analysis was not
signiﬁcantly different between the control and HS group
(all P > .1).
The pathologic analysis of the postmortem liver tissue
demonstrated focal necrosis, inﬂammation, and diffuse
hepatic sinusoidal dilatation with an inter-rater reliability
of 0.83 between the two pathologists but did not demon-
strate any histologic difference (P ¼ .49; Fig 3). Table II is
included as a reference to the measures that occurred
hourly during the 6-hour resuscitative phase. In regards
to hemodynamics, there was a signiﬁcant difference
between the sham and control group but no difference
between the control and experimental groups. The labora-
tory analysis of the study demonstrates that there was
a signiﬁcant decrease in the acidosis and coagulopathy at
the end of the resuscitative period.DISCUSSION
Pharmacologic adjuncts have demonstrated signiﬁcant
promise in minimizing metabolic and resuscitative require-
ments after an ischemia-reperfusion injury in swine and
murine models.5,16,17 HS is a medication of this class and
is thought to work by minimizing the activation of the
systemic inﬂammatory cascade that occurs after ischemia-
reperfusion injuries and allows reduction in cytotoxic
inﬂammatory mediators and the downregulation of L-
selectin expression, causing a reduced neutrophil extravasa-
tion and tissue inﬁltration.5,18 Within our own laboratory,
we demonstrated that valproic acid minimized aortic endo-
thelial cell injury and resuscitative requirements with this
same model when administered at the time of cross-
clamp.4 However, for these medications to enter clinical
practice, preclinical studies are essential to analyze the
effect and preclinical response to novel therapeutics.
The current study looked at each of these three areas
and determined, ﬁrst, that HS was safe for administration,
with no adverse events. Second, supraceliac aortic cross-
clamping causes a profound increase in MAP, cardiac
output, and HR in a uniform and predictable manner
(Fig 1), resulting in signiﬁcantly increased cardiac workload
or “stress.” HS administration at the time of this cross-
clamp also demonstrated a predictable clinical temporal
response, with an increase in the MAP, HR, and cardiac
output, and followed similar hemodynamic curves;
however, the hyperdynamic response was signiﬁcantly
blunted compared with control animals.
In this study, the greatest clinical beneﬁt was in mini-
mizing the work of and stress on the left heart (MAP
and HR); however, HS administration decreased only
these hemodynamic measures. The lack of change in the
systemic vascular resistance likely represents the mechanical
effect of the cross-clamp, which likely may not be over-
come with pharmacologic treatment. In addition, no
signiﬁcant changes were seen with the pressures on
the right heart, which may be advantageous clinically
Table II. Hemodynamic parameters and laboratory values of the resuscitative phase in the study groups
Variables
Hour of resuscitation
1 2 3 4 5 6
Hemodynamic parametersa
Hemodynamics
MAP, mm Hg
Sham 69 6 27.9 63.3 6 17.1 61.0 6 14.2 55.1 6 13.0 47.1 6 8.30 64.1 6 72.9
HS 45.7 6 8.54 51.1 6 27.4 58.8 6 63.6 53.8 6 41.2 50.1 6 26.5 50.1 6 14.0
Hemorrhagic shock 65.9 6 21.1 59.8 6 9.30 55.1 6 6.67 52.6 6 5.10 52.7 6 8.42 58.1 6 17.7
HR, beats/min
Sham 81.9 6 21.9 95.3 6 23.3 99.2 6 31.2 99.1 6 32.8 100.0 6 40.4 95.5 6 27.6
HS 121.0 6 28.5 123.0 6 37.8 121.0 6 44.3 122.0 6 49.8 144.0 6 30.2 144.0 6 42.4
Hemorrhagic shock 149.0 6 34.1 165.0 6 21.4 175.0 6 16.5 177.0 6 18.0 172.0 6 16.1 161.0 6 19.9
Temperature, C
Sham 36.8 6 1.15 37.1 6 0.88 37.2 6 1.00 37.7 6 0.99 38.0 6 1.04 37.9 6 0.88
HS 35.8 6 0.66 36.4 6 0.87 36.9 6 1.17 37.4 6 1.29 37.7 6 1.55 37.8 6 1.62
Hemorrhagic shock 35.8 6 1.39 36.5 6 1.21 37.1 6 1.22 37.4 6 1.17 37.4 6 0.90 37.1 6 0.80
Cardiac output, L/min
Sham 4.19 6 1.23 4.04 6 0.51 2.87 6 1.98 3.05 6 1.53 3.31 6 0.54 3.48 6 0.68
HS 3.44 6 1.87 4.14 6 1.59 4.38 6 1.19 4.46 6 1.21 5.58 6 1.73 6.31 6 1.87
Hemorrhagic shock 5.41 6 2.02 5.27 6 2.39 4.72 6 1.64 5.82 6 1.95 6.0 6 2.67 6.55 6 2.48
Central venous pressure, mm Hg
Sham 4.18 6 5.54 3.32 6 2.87 4.77 6 6.49 4.34 6 6.10 2.74 6 2.32 4.03 6 3.94
HS 3.85 6 4.56 2.40 6 2.42 2.16 6 2.77 2.37 6 1.78 4.69 6 3.84 3.82 6 3.97
Hemorrhagic shock 4.79 6 5.21 1.54 6 1.38 1.68 6 2.17 2.75 6 2.16 3.75 6 1.91 4.26 6 2.70
Left ventricular stroke work index,
g-m/m2
Sham 32.3 6 8.85 31.9 6 11.7 36.4 6 27.2 24.3 6 10.8 22.8 6 13.1 23.3 6 4.07
HS 28.0 6 20.6 33.0 6 24.5 30.9 6 23.7 31.6 6 18.9 28.0 6 12.8 31.2 6 10.3
Hemorrhagic shock 20.9 6 9.87 21.2 6 9.45 16.8 6 8.07 21.3 6 7.95 22.2 6 10.0 28.9 6 17.1
Mean pulmonary artery pressure,
mm Hg
Sham 13.6 6 5.04 14.8 6 4.80 15.7 6 6.92 16.8 6 8.62 15.7 6 8.25 17.7 6 10.2
HS 12.4 6 5.25 12.0 6 5.28 12.1 6 4.29 12.1 6 5.17 14.5 6 6.99 16.3 6 6.65
Hemorrhagic shock 15.6 6 5.39 15.3 6 7.83 14.5 6 8.06 14.9 6 9.71 14.4 6 7.33 15.8 6 9.27
Pulmonary artery wedge pressure,
mm Hg
Sham 1.92 6 1.38 1.90 6 1.13 2.66 6 2.34 3.3 6 3.88 1.5 6 0.84 1.84 6 0.98
HS 2.7 6 2.67 2.05 6 2.14 2.18 6 2.12 2.14 6 1.90 2.27 6 1.67 1.37 6 1.50
Hemorrhagic shock 2.33 6 3.11 3.25 6 4.15 1.72 6 2.24 2.12 6 2.23 1.54 6 0.82 2.07 6 1.20
Pulmonary vascular resistance index,
dynes  sec  cm5
Sham 269.0 6 56.2 305.0 6 69.5 292.0 6 56.0 356.0 6 104.0 275.0 6 98.3 364.0 6 68.4
HS 101.0 6 64.3 128.0 6 93.3 175.0 6 95.7 172.0 6 138.0 169.0 6 115.0 180.0 6 102.0
Hemorrhagic shock 238.0 6 151.0 255.0 6 212.0 147.0 6 133.0 175.0 6 131.0 234.0 6 154.0 275.0 6 135.0
Right ventricular stroke work index,
m/m2
Sham 5.38 6 2.55 6.37 6 1.70 6.64 6 2.54 6.27 6 1.58 4.98 6 1.74 5.44 6 1.50
HS 7.23 6 5.02 7.41 6 3.84 6.19 6 2.90 5.04 6 4.49 5.97 6 4.84 7.55 6 3.91
Hemorrhagic shock 4.40 6 2.78 5.65 6 2.81 4.2 6 1.90 5.24 6 3.99 4.70 6 3.76 6.54 6 4.56
Stroke volume index, mL/beat/m2
Sham 36.7 6 5.09 38.5 6 8.07 38.1 6 11.3 32.9 6 8.07 30.0 6 9.39 33.5 6 4.61
HS 51.0 6 28.9 48.9 6 25.7 43.9 6 28.4 42.1 6 21.9 45.9 6 24.4 43.3 6 14.5
Hemorrhagic shock 28.1 6 10.5 26.8 6 7.60 23.7 6 8.53 29.2 6 10.4 29.6 6 11.0 34.6 6 14.8
Systemic vascular resistance index,
dynes  sec  cm5/m2
Sham 1511 6 498 1410 6 449 1420 6 482 1336 6 377 1324 6 144 1385 6 372
HS 637 6 265 720 6 242 785 6 215 929 6 602 670 6 240 794 6 630
Hemorrhagic shock 889 6 286 1002 6 266 1132 6 330 955 6 322 892 6 329 1003 6 476
Laboratory analysisb
INR
Sham 0.96 6 0.15 0.92 6 0.17 1.04 6 0.26 0.91 6 0.19 1.10 6 0.27 1.06 6 0.31
HS 1.11 6 0.14 1.10 6 0.15 1.10 6 0.15 1.16 6 0.16 1.22 6 0.19 1.30 6 0.28
Control 1.65 6 0.45 1.44 6 0.30 1.44 6 0.25 1.42 6 0.20 2.03 6 1.01 2.51 6 1.60
(Continued on next page)
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Table II. Continued.
Variables
Hour of resuscitation
1 2 3 4 5 6
Lactate, mmol/L
Sham 3.4 6 0.52 2.27 6 0.79 2.27 6 0.73 2.27 6 0.77 2.79 6 1.55 2.55 6 1.38
HS 9.60 6 1.04 8.78 6 1.35 8.37 6 1.81 7.75 6 2.28 7.60 6 3.04 8.11 6 2.66
Control 11.8 6 1.27 11.5 6 1.52 11.7 6 1.85 12.0 6 1.44 12.7 6 1.42 12.7 6 1.40
pH
Sham 7.49 6 0.05 7.51 6 0.06 7.49 6 0.06 7.50 6 0.06 7.47 6 0.08 7.48 6 0.08
HS 7.22 6 0.08 7.26 6 0.08 7.26 6 0.07 7.25 6 0.08 7.24 6 0.11 7.22 6 0.09
Control 7.10 6 0.09 7.10 6 0.08 7.04 6 0.11 7.06 6 0.07 6.99 6 0.08 6.97 6 0.05
HR, Heart rate; HS, hydrogen sulﬁde; INR, international normalized ratio; MAP, mean arterial pressure.
aHemodynamics were statistically different comparing sham with the hemorrhagic shock group, but there were no statistical differences between the groups
when the sham group was excluded from the analysis.
bThere were statistically signiﬁcant differences in the control and HS groups, with signiﬁcantly signiﬁcant decreases in end-point lactate measures, acidosis
(pH), and coagulopathy (INR). Data for the sham group are provided as a reference.
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status.
With supraceliac aortic clamping, the left heart receives
the most stress, and HS independently demonstrated an
attenuation of the hyperdynamic cardiovascular response
to cross-clamping. This hyperdynamic cardiovascular atten-
uation demonstrates a promising area of study in the phys-
iologic response to vascular occlusion. By reducing the
work of the left heart during cross-clamping, HS may
provide a cardioprotective beneﬁt that persists not only
during the cross-clamp but also by improving cardiovas-
cular function after release and during resuscitation
through decreased cardiac stress and also through “cellular
priming” and reducing cellular demand. This is important,
because modern clinical practice often requires a delicate
balance of pharmacologic adjuncts to minimize the cardio-
vascular and endotoxemic stress that occurs during aortic
clamping.19,20 These strategies involve administration of
b-blockade and vasodilatory agents to minimize the cardiac
stress and attenuate the hyperdynamic cardiac response,
a goal that was achieved with HS.21,22 In addition to these
clinically favorable actions, HS may also play a signiﬁcant
role in minimizing the inﬂammatory response to
ischemia-reperfusion and minimizing the overall systemic
inﬂammatory response syndrome that leads to end-organ
damage and increased resuscitative requirements.12,23,24
Our results lend some support to this inﬂammatory
theory by demonstrating that HS was also beneﬁcial in
minimizing physiologic resuscitative requirements and
systemic inﬂammatory response syndrome components
such as tachycardia. There was a profound decrease in
vasopressor requirements and an overall reduction in intra-
venous ﬂuid volume required to maintain stable circulatory
hemodynamics. This is important, because a decrease in
the activation of the physiologic systemic inﬂammatory
response may demonstrate that cellular metabolic demand
is diminished because the cells are “primed” against physi-
ologic cytokine and oxidative injury. Other studies
have demonstrated similar ﬁndings that preinjury orpoint-of-injury pharmacologic adjuncts may provide the
next large advancement in ischemia-reperfusion therapy
by targeting demand-side physiology (reduction of cellular
metabolic demand) and, thereby, improving cellular toler-
ance to ischemia while also modulating inﬂammatory cyto-
kine release.6,23,24
Our study has some limitations. First, this study was
performed during a relatively short 8-hour clinical period
(hemorrhage, cross-clamp, and 6-hour resuscitation). We
also did not document the profound histologic changes
that have been observed in prior studies with HS adminis-
tration.6 This may have been due to the organ examined
(kidney vs liver), the administration protocol (before
cross-clamp or after), or the dosing of HS.
In addition, the current study is in a fatal model, and
future studies may demonstrate different effects in a nonle-
thal model that would more closely model elective opera-
tions and extremity ischemia-reperfusion. However, we
chose this model to determine whether there was an effect
with a large animal ischemia-reperfusion insult, a study that
had not been previously conducted.
HS may also ultimately provide clinical beneﬁt in future
medical practice, particularly with ischemia and reperfusion
events. Many vascular procedures involve potential
bleeding, and those with arterial reconstruction have an
ischemia and reperfusion phase. HS has demonstrated in
our study to minimize the work of the heart, and this
may apply to scenarios in which there is not such
a profound hyperdynamic response. Arterial clamping
does increase the stress of the heart and induce an inﬂam-
matory response. Many patients have underlying cardiovas-
cular disease, and minimizing left heart stress would be
a beneﬁcial adjunct to treatment, which we have demon-
strated is possible with HS.
CONCLUSIONS
This is the ﬁrst study, to our knowledge, to evaluate
the effect of HS on the direct cardiovascular effects of an
aortic cross-clamp and subsequent resuscitation. This study
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cardiovascular response to supraceliac aortic cross-
clamping. HS allows not only for improved cardiovascular
hemodynamics but also for a major resuscitative beneﬁt,
with reduction of intravenous ﬂuid and pressor require-
ments. This study demonstrates that pharmacologic
therapy may minimize the stress of a cross-clamp on the
left heart, decrease the inﬂammatory activation, and
improve subsequent resuscitation. We believe this model
may serve as platform for further investigating the physi-
ology during aortic cross-clamping and for studying phar-
macologic agents that may provide signiﬁcant metabolic
and resuscitative beneﬁts.
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